A practical reference on Bremelanotide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-30 and is reviewed periodically as new material appears.
The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Lyophilized powder form |
| Solubility class | Freely soluble in water | Also dissolves in polar organic solvents |
| Typical storage temperature | Minus 20 degrees Celsius or lower | Desiccated and protected from light |
| Typical analytical method | Reversed-phase HPLC with UV detection | Purity reported by area normalization |
| Common synonyms | PT-141; bremelanotide | Research code and assigned generic name |
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
== Structure == These proteins are characterized by having three disulfide bonds in a characteristic motif. Some family members have an additional disulfide bond also in a conserved location. All of these proteins have a helical segment (corresponding to B chain in insulin) followed by a variable-length chain, followed by a domain (A chain in insulin) with two helices pinned against each other via a disulfide bond. These two regions are linked by two or three disulfide bonds. Amongst the different proteins in the family, very little of the sequence is conserved except for the disulfide bonds. The variable-length chains may exhibit large inter-species variation even when the remainder of the sequence is highly conserved; and as is in the case of insulin, sometimes the variable length chain is cleaved out by secretory endoproteases, leaving a two-chain protein held together by disulfide bonds.
Nalorphine (INNTooltip International Nonproprietary Name; also known as N-allylnormorphine; brand names Lethidrone and Nalline) is a mixed opioid agonist–antagonist with opioid antagonist and analgesic properties. It was introduced in 1954 and was used as an antidote to reverse opioid overdose and in a challenge test to determine opioid dependence. Nalorphine was the second opioid antagonist to be introduced, preceded by nalodeine (N-allylnorcodeine) in 1915 and followed by naloxone in 1960 and naltrexone in 1963. Due to potent activation of the κ-opioid receptor, nalorphine produces side effects such as dysphoria, anxiety, confusion, and hallucinations, and for this reason, is no longer used medically.
=== Normal tissue structure and wound response === Normal tissues consist of parenchymal cells and stromal cells. The parenchymal cells are the functional units of an organ. In contrast, the stromal cells provide the structure of the organ and secrete extracellular matrix as supportive, connective tissue. In normal epithelial tissues, epithelial cells, or parenchymal cells of epithelia, are highly organized, polar cells. These cells are separated from stromal cells by a basement membrane that prevents these cell populations from mixing. A mixture of these cell types is recognized, normally, as a wound, as in the example of a cut to the skin. Metastasis is an example of a disease state in which a breach of the basement membrane barrier occurs.
Chevreul's scientific work covered a wide range, but he is best known for the classical researches he carried out on animal fats, published in 1823 (Recherches sur les corps gras d'origine animale). These enabled him to elucidate the true nature of soap; he was also able to discover the composition of stearin, a white substance found in the solid parts of most animal and vegetable fats, and olein, the liquid part of any fat, and to isolate stearic and oleic acids, the names of which he invented. This work led to important improvements in the processes of candle-manufacture. Chevreul was a determined enemy of charlatanism in every form, and a complete sceptic as to the "scientific" psychical research or spiritualism which had begun in his time. His research on the "magic pendulum", Dowsing rods and table-turning is revolutionary. In an open letter to André-Marie Ampère in 1833, and his 1854 paper "De la baguette", Chevreul explains how human muscular reactions, totally involuntary and subconscious, are responsible for seemingly magical movements. In the end, Chevreul discovered that once a person holding divining rods/magic pendulum became aware of the brain's reaction, the movements stopped and could not be willingly reproduced. His was one of the earliest explanations of the ideomotor effect.
== Academic career == In 1974, Candace Pert earned a Ph.D. in pharmacology from Johns Hopkins University School of Medicine, where she worked in the laboratory of Solomon Snyder and discovered the brain's opiate receptor. Pert conducted a National Institutes of Health Postdoctoral Fellowship with the Department of Pharmacology at the Johns Hopkins University School of Medicine from 1974 to 1975. She conducted research at the National Institute of Mental Health from 1975 to 1987. In 1983, she became the Chief of the Section on Brain Biochemistry of the Clinical Neuroscience Branch, the only female chief at NIMH. She left to found and direct a private biotech laboratory in 1987. Pert was a research professor in the department of physiology and biophysics at Georgetown University School of Medicine in Washington, D.C. In her latter years, she was with RAPID Pharmaceuticals. In 1997 she published her book Molecules of Emotion. She appeared as one of the experts in Bill Moyers 1993 PBS video production, "Healing and the Mind", and in the 2004 film What the #$*! Do We Know!?. She died on September 12, 2013, in Potomac, Maryland.
Sources: en.wikipedia.org
Today, scientific interest in snail and slug mucus has grown due to its potential biomedical and cosmetic applications. In the present day, slug slime is being studied for its antimicrobial properties and healing properties with research being done on drug delivery systems as well as cancer therapy. Scientific interest in snail and slug mucus has also grown in recent decades, particularly after glycosaminoglycans (GAGs), important compounds for skin health and repair, were first extracted from the African giant snail, Achatina fulica in 1996.
6 July – Inverness, Skye and West Ross-shire becomes the final constituency to declare its election results, and sees the number of Liberal Democrat MPs rise to 72 after they defeat the SNP to win the seat. At his first press conference since taking office, Starmer announces that he wants to cut instances of re-offending to reduce the prison population. James Timpson is appointed as Minister of State for Prisons, Parole and Probation. Starmer announces the Rwanda asylum plan is "dead and buried". 7 July – Starmer makes his first visit to Scotland as prime minister, for a meeting with First Minister John Swinney. Jacqui Smith is appointed as Minister of State for Skills, Apprenticeships and Higher Education, while Douglas Alexander becomes Business Minister. The Starmer administration announces that the final two migrants due to be deported to Rwanda will be released on bail in the next few days; a further 218 are confirmed to have been released on bail by the Sunak administration before the election. Home Secretary Yvette Cooper outlines plans to establish a UK Border Security Command whose task it will be to reduce small boat crossings in the English Channel. 8 July – Chancellor Rachel Reeves announces plans to bring back compulsory housebuilding targets as part of plans to reboot the UK economy. Education Secretary Bridget Phillipson writes to all teachers in the education sector saying she wants to "reset the relationship" with the sector as part of plans to recruit an extra 6,500 teachers.
When inhaled, plutonium can pass into the bloodstream. Once in the bloodstream, plutonium moves throughout the body and into the bones, liver, or other body organs. Plutonium that reaches body organs generally stays in the body for decades and continues to expose the surrounding tissue to radiation and thus may cause cancer. A commonly cited quote by Ralph Nader states that a pound of plutonium dust spread into the atmosphere would be enough to kill 8 billion people. This was disputed by Bernard Cohen, an opponent of the generally accepted linear no-threshold model of radiation toxicity. Cohen estimated that one pound of plutonium could kill no more than 2 million people by inhalation, so that the toxicity of plutonium is roughly equivalent with that of nerve gas. Several populations of people who have been exposed to plutonium dust (e.g. people living down-wind of Nevada test sites, Nagasaki survivors, nuclear facility workers, and "terminally ill" patients injected with Pu in 1945–46 to study Pu metabolism) have been carefully followed and analyzed. Cohen found these studies inconsistent with high estimates of plutonium toxicity, citing cases such as Albert Stevens who survived into old age after being injected with plutonium. "There were about 25 workers from Los Alamos National Laboratory who inhaled a considerable amount of plutonium dust during 1940s; according to the hot-particle theory, each of them has a 99.5% chance of being dead from lung cancer by now, but there has not been a single lung cancer among them."
Biotechnology in the general sense has been an important part of biology since the late 19th century. With the industrialization of brewing and agriculture, chemists and biologists became aware of the great potential of human-controlled biological processes. In particular, fermentation proved a great boon to chemical industries. By the early 1970s, a wide range of biotechnologies were being developed, from drugs like penicillin and steroids to foods like Chlorella and single-cell protein to gasohol—as well as a wide range of hybrid high-yield crops and agricultural technologies, the basis for the Green Revolution.
Sources: en.wikipedia.org
Chemical degradation such as hydrolysis and oxidation proceeds more slowly as temperature falls. Cold storage also limits microbial growth in reconstituted material. Repeated warming should be avoided because thermal cycling stresses the peptide.
Retention time supports consistency but does not establish structure by itself. A different compound can elute at a similar time under one set of conditions. Mass spectrometry or comparison with a verified standard is normally required alongside the chromatographic result.
The lactam bridge constrains the peptide backbone and limits attack by some exopeptidases. It does not protect against hydrolysis of amide bonds inside the ring or against oxidative modification of susceptible residues. Stability therefore still depends heavily on storage conditions.
PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.